LOXO-338 + Pirtobrutinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
Trial Timeline
Sep 30, 2021 → Jun 1, 2026
NCT ID
NCT05024045About LOXO-338 + Pirtobrutinib
LOXO-338 + Pirtobrutinib is a phase 1 stage product being developed by Eli Lilly for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT05024045. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05024045 | Phase 1 | Active |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell